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The gut microbiota plays a key role in host meta-
bolism. Toll-like receptor 5 (TLR5), a flagellin re-
ceptor, is required for gut microbiota homeostasis.
Accordingly, TLR5-deficient (T5KO) mice are prone
to develop microbiota-dependent metabolic syn-
drome. Here we observed that T5KO mice display
elevated neutral lipids with a compositional in-
crease of oleate [C18:1 (n9)] relative to wild-type lit-
termates. Increased oleate contribution to hepatic
lipids and liver SCD1 expression were both micro-
biota dependent. Analysis of short-chain fatty acids
(SCFAs) and 13C-acetate label incorporation re-
vealed elevated SCFA in ceca and hepatic portal
blood and increased liver de novo lipogenesis in
T5KO mice. Dietary SCFAs further aggravated meta-
bolic syndrome in T5KO mice. Deletion of hepatic
SCD1 not only prevented hepatic neutral lipid oleate
enrichment but also ameliorated metabolic syn-
drome in T5KO mice. Collectively, these results un-
derscore the key role of the gut microbiota-liver
axis in the pathogenesis of metabolic diseases.
INTRODUCTION
Metabolic syndrome is a constellation of metabolic abnormal-
ities associated with insulin resistance that leads to metabolic
diseases such as obesity, type II diabetes, and hepatic and car-
diovascular diseases. The etiology of metabolic syndrome is
influenced by genetics and a number of environmental factors
including gut microbiota (Ley et al., 2006; Turnbaugh et al.,Cell M2006). Potential mechanisms by which the microbiota influ-
ences host metabolism include increased calorie extraction
(Ley et al., 2006; Turnbaugh et al., 2006), metabolic endotoxe-
mia (Cani et al., 2008), and generation of toxic metabolites
(Wang et al., 2011). Previously, we have demonstrated that
mice lacking TLR5 (T5KO) are susceptible to spontaneous
gut inflammation and metabolic syndrome and exhibit micro-
biotal dysbiosis (Carvalho et al., 2012; Vijay-Kumar et al.,
2007, 2010). Further, T5KO mice maintained on a high-fat
diet (HFD) develop hepatic steatosis and insulitis. Specifically,
the gut microbiota in T5KO mice induces low-grade, chronic,
systemic inflammation resulting in desensitization of insulin re-
ceptors culminating in hyperphagia and metabolic syndrome
(Vijay-Kumar et al., 2010).
Microbiota exerts a substantial influence on host lipid meta-
bolism (Rabot et al., 2010; Velagapudi et al., 2010). One such
pathway is the generation of short-chain fatty acids (SCFAs)
such as acetate, butyrate, and propionate via anaerobic fermen-
tation of dietary fiber. SCFAs not only serve as a major fuel
(i.e., butyrate) for the colonocytes but also are absorbed via
enterohepatic circulation and contribute to hepatic lipogenesis
(den Besten et al., 2013a; Samuel et al., 2008; Wolever et al.,
1989). The major de novo synthesized lipotoxic saturated fatty
acids (SFAs) in the liver are palmitic acid (C16:0) and stearic
acid (C18:0), which are converted into the less lipotoxic monoun-
saturated fatty acids (MUFAs) palmitoleate (C16:1 n7) and oleate
(C18:1 n9), a steatogenic agent. The addition of a double bond is
catalyzed by hepatic microsomal, lipogenic rate-limiting enzyme
stearoyl CoA desaturase-1 (SCD1), a key regulatory enzyme in
the homeostasis of SFA and MUFA (Hodson and Fielding,
2013). Despite oleate being a major MUFA from the diet, the
expression of SCD1 is highly regulated by developmental, die-
tary, hormonal, and environmental factors. MUFA participates
in the regulation of diverse processes, serve as better sub-
strates for the synthesis of hepatic neutral lipids (triglyceridesetabolism 22, 983–996, December 1, 2015 ª2015 Elsevier Inc. 983
Figure 1. Elevated Oleate (C18:1)-Enriched Hepatic Neutral Lipids and Insulin Resistance in T5KO Mice
(A–F) Age-matched T5KO male mice and their WT littermates (20 week old, n = 10 to 11) were monitored for (A) body weight, (B) fat pad, (C) 15 hr fasting blood
glucose, (D) fasting serum insulin, (E) serum total cholesterol (TC), and (F) serum TGs.
(G–J) Hepatic lipids were analyzed after 5 hr of fasting. (G) TG, (H) CEs, (I) FC, and (J) PLs.
(K–N) Fatty acid composition of hepatic lipid fractions were analyzed by gas chromatography and represented as (%) C18:1 (K) C18:1 in total lipid, (L) C18:1 in CE,
(M) C18:1 in TG and (N) C18:1 in PL.
(O) Immunoblot representing insulin-induced phosphorylation of AKT (Thr308) and total AKT in liver, soleus skeletal muscle, and adipose tissue.
(P) Insulin sensitivity.
(Q) Liver total lipid oleate (%) levels were quantified in male T5KO and their WT littermates (n = 6) at different age 3, 5, 8, and 12 weeks. Data are represented as
mean ± SEM. *p < 0.05.[TGs] and cholesterol esters [CEs]), and thus play a role in
increasing tissue lipid load and may initiate insulin resistance
(Miyazaki et al., 2000). Accordingly, SCD1 deficiency protects
against high-fat-, high-carbohydrate-, and leptin-deficiency-
induced obesity and hepatic steatosis (Miyazaki et al., 2004;
Miyazaki et al., 2009). Leptin-deficient mice exhibit increased984 Cell Metabolism 22, 983–996, December 1, 2015 ª2015 ElsevierSCD1 expression and associated with elevated levels of C16:1
and C18:1 in liver lipids.
SCD1 negatively regulates inflammation possibly by control-
ling the homeostasis of MUFA and SFA. Specifically, inhibition
of SCD1 exacerbates responses to exogenous pro-inflammatory
challenges such as lipopolysaccharide (LPS), C. rodentium, andInc.
a chemical colitogen DSS (Chen et al., 2008). Further, accumu-
lation of SFA in Scd1KO mice promote inflammation via TLR4
signaling and promote atherosclerosis (Fessler et al., 2009),
whereas loss of SCD1 attenuates adipose tissue inflammation
(Liu et al., 2010), suggesting that its activity in diverse tissues
has distinct outcomes.
In this study, we hypothesized that T5KO mice, which exhibit
microbiota-dependent metabolic syndrome, may have altered
hepatic lipogenesis that might promote an obese pheno-
type. Accordingly, we demonstrate that T5KO mice displayed
elevated hepatic C18:1 in neutral lipids when compared to
wild-type (WT) littermates. This difference was not seen in
microbiota-ablated and germ-free (GF) T5KO mice. 1H NMR
metabolic profiling of cecal contents indicated decreased cecal
oligosaccharides and elevated SCFA, suggesting profound
changes in bacterial fermentation. Further, colonic SCFA re-
ceptors, hepatic lipogenic enzymes including SCD1, and pro-
inflammatory genes were upregulated in T5KO mice. Using
13C-acetate labeling, we showed that gut-derived SCFA re-
ached to the liver and incorporated into both liver and plasma
palmitate (C16:0) relatively to a greater extent in T5KO mice.
Dietary SCFA further aggravated metabolic syndrome while he-
patic deletion of SCD1 in T5KO mice prevented most of the
indices of metabolic syndrome. Hence, the ability of T5KO
mice to synthesize higher MUFA, probably as a ‘‘metabolic
adaptation’’ to protect from lipotoxicity of SFA synthesized
from SCFA but then potentiate metabolic syndrome. Even
though numerous beneficial properties have been attributed
to SCFA, their excess in conditions of innate immune deficiency
coupled with bacterial overgrowth may increase susceptibility
to metabolic diseases.
RESULTS
Insulin Resistance in T5KO Mice Is Associated with
Oleate-Enriched Hepatic Neutral Lipids
T5KO mice exhibit hallmark features of metabolic syndrome
including hyperlipidemia. To investigate the extent to which
serum hyperlipidemia is reflected in the liver, we analyzed liver
TGs, CEs, free cholesterol (FC), phospholipids (PLs), insulin
sensitivity, and signaling in 20-week-old T5KO mice and their
WT littermates. As observed in other facilities (Emory and
Georgia State University), T5KO mice housed at PSU displayed
higher body weights, abdominal adiposity, hyperglycemia (Fig-
ures 1A–1C) with associated splenomegaly (Figure S1A), and
elevated colonic expression of pro-inflammatory genes (Lipo-
calin 2 (Lcn2), iNos, Pro-Il-1b, and Kc) (Figures S1B–S1E), indi-
cating a low-grade chronic inflammatory state. Further, T5KO
mice were hyperinsulinemic and hyperlipidemic (Figures 1D–
1F). T5KO mice displayed elevated hepatic neutral lipids TG
and CE compared to WT littermates (Figures 1G and 1H). There
was no significant difference in the liver FC, but a significant
decrease in PL levels in T5KO mice was observed (Figures 1I
and 1J, respectively). A similar trend of elevated lipid parame-
ters was observed in the female T5KO mice (data not shown).
Obesity in leptin-deficient mice is associated with elevated
tissue MUFA levels and is SCD1 dependent (Sekiya et al.,
2003). Similar to leptin-deficient mice, T5KO mice exhibited
elevated plasma insulin, an anabolic hormone known to upregu-Cell Mlate SCD1 (Jeffcoat et al., 1979). We therefore examined whether
obese T5KO mice displayed similar MUFA-enriched lipids. Liver
lipid analysis in T5KOmice showed an increase (25.0%) in C18:1
in the total liver lipids (Figure 1K), mainly attributed to increased
C18:1 in the CE (16.0%) and TG (9.0%) fractions (Figures 1L and
1M). The C18:1 level in PL fraction was comparable betweenWT
and T5KOmice (Figure 1N). Interestingly, palmitoleate (C16:1), a
minor product of SCD1, was comparable in the total lipid
(although with large variation), TG, CE, and PL fractions of
T5KO mice and WT littermates (Figures S1F–S1I). Notably,
mRNA transcript of lipogenic genes in adipose and skeletal mus-
cle remained unaltered in T5KO mice (Figures S1J and S1K). In
general, female mice tend to have higher levels of MUFA in the
liver when compared to males (Lee et al., 1996), but we did not
observe such sex based differences (data not shown). In the
total liver lipids, a decreasing trend in essential fatty acids
(EFAs) linoleic acid (C18:2 n6) and arachidonic acid (C20:4 n6)
was observed but not significant (data not shown). Similarly, in
the liver CE, but not the TG fraction, C18:2 levels were decreased
in T5KO mice relative to WT littermates (data not shown). T5KO
mice with elevated hepatic lipids displayed insulin resistance,
as measured by phosphorylation of AKT, an insulin-responsive
protein, and whole-body insulin sensitivity test (Figures 1O
and 1P). Similar to male, female T5KOmice also exhibited meta-
bolic syndrome with hepatic lipid oleate enrichment (Figures
S2A–S2J).
Given that both diet and gut microbiota composition change
drastically at the suckling-to-weaning transition, we next asked
whether the elevated C18:1 in hepatic lipids of T5KO mice is
present beginning from birth or occurs after weaning. At the
age of 3 weeks, mice were weaned on chow diet, and liver total
C18:1 was measured at 3, 5, 8, and 12 weeks of age. At the
time of weaning, both WT and T5KO mice displayed similar
levels of C18:1 in liver, which increased within 2 weeks of
weaning in both WT and T5KO mice (Figure 1Q). However,
the percent increase in C18:1 in T5KO mice was significantly
higher than in WT littermates. In addition to C18:1, liver total
TG levels increased with age in T5KO mice (data not shown).
Thus, the elevated C18:1 in the liver is an acquired character-
istic after weaning perhaps due to the dietary switch from suck-
ling to lab chow. In contrast to leptin-deficient mice, the
elevated C18:1 was not seen in either serum or adipose tissue,
while fecal lipids of T5KO mice are comparable to WT litter-
mates (Table S2).
Upregulation of Hepatic Lipogenic, Pro-Inflammatory,
and Insulin Resistance Genes in T5KO Mice
Excessive hepatic lipogenesis may lead to liver inflammation
and contribute to hepatic insulin resistance. Therefore, we
next sought to determine whether increased lipid deposition
associated with altered hepatic gene expression. Notably, the
hepatic mRNA transcripts of lipogenic genes (sterol regulatory
element binding protein 1c [Srebp1c], acetyl-CoA carboxylase
[Acc], fatty acid synthase [Fas], Scd1, 3-hydroxy-3-methyl-glu-
taryl-CoA [HMG-CoA] reductase [Hmgcr], and HMG-CoA syn-
thase [Hmgcs]) and enzymes responsible for the esterification
of MUFA to cholesterol and TG via acyl CoA: cholesterol
acyl transferase 2 (Acat2) and diacylglycerol acyl transferase
1 and 2 (Dgat1 and 2) were elevated in T5KO mice (Figuresetabolism 22, 983–996, December 1, 2015 ª2015 Elsevier Inc. 985
Figure 2. Enhanced Expression of Hepatic Lipogenic Enzymes, Pro-Inflammatory, and Insulin Resistance Genes in T5KO Mice
Hepatic expression of lipogenic enzymes, inflammatory, and insulin resistance marker genes were analyzed inmale T5KOmice and their WT littermates (20 week
old, n = 5).
(A–P) (A) Sterol regulatory element binding protein 1c (Srebp1c), (B) Acc, (C) Fas, (D) stearoyl-CoA desaturase-1 (Scd1), (E) immunoblot for SCD1, (F) acyl
CoA:cholesterol acyltransferase 2 (Acat2), (G) diacylglycerol acyltransferase 1 (Dgat1), (H) Dgat2, (I) Hmgcs, (J) Hmgcr, (K) tumor necrosis factor alpha (Tnfa), (L)
Lipocalin2 (Lcn2), (M) keratinocyte-derived chemokine (Kc), (N) forkhead box protein O1 (Foxo1), (O) peroxisome proliferator-activated receptor-gamma co-
activator-1 alpha (Pgc-1a), and (P) phosphoenolpyruvate carboxykinase (Pepck). Data are represented as mean ± SEM. *p < 0.05.2A–2D and 2F–2J), including SCD1 at the protein level (Fig-
ure 2E). Interestingly, mRNA transcripts of key inflammatory cy-
tokines Tnfa, Lcn2, and chemokine (C-X-C motif) ligand 1 (Kc)
were augmented in T5KO mice (Figures 2K–2M). Further, the
T5KO mice also showed increased expression of genes asso-
ciated with insulin resistance such as Forkhead box protein O1
(Foxo1), peroxisome proliferator-activated receptor gamma co-
activator 1 alpha (Pgc1a) transcription coactivator, and gluco-
neogenic enzyme phosphoenolpyruvate carboxykinase (Pepck)986 Cell Metabolism 22, 983–996, December 1, 2015 ª2015 Elsevier(Figures 2N–2P). Collectively, these results suggest that the
elevated C18:1 in T5KO mice is a result of increased upregu-
lation of a spectrum of lipogenic genes associated with
markers of inflammation and insulin resistance. In accordance
with unaltered fatty acid composition of adipose tissue in
WT and T5KO mice, we did not observe any significant differ-
ences in the transcripts of above lipogenic genes in adipose
tissue and skeletal muscles of these mice (Figures S1J and
S1K).Inc.
Figure 3. HFD-Fed and Calorie-Restricted T5KO Mice Exhibit Elevated Oleic Acid in Hepatic Neutral Lipids
(A–E) Age-matched female T5KO mice and their WT littermates (12 week old, n = 5) maintained on a HFD for 8 weeks and 5 hr fasting serum and liver were
analyzed for following parameters: (A) blood glucose, (B) insulin sensitivity test, (C) fasting serum insulin, (D) serum TC, and (E) serum TG.
(F–K) (F) Liver TG, (G) C18:1 in total lipid, (H) C18:1in TG, (I) C18:1 in CE, (J) total C18:2, and (K) total C20:4.
(L) mRNA expression of hepatic lipogenic, inflammatory, and insulin resistance genes in HFD-fed WT and T5KOmice. Age-matched female T5KOmice and their
WT littermates (n = 5) were subjected to calorie restriction for 12 weeks and hepatic TG and C18:1 were analyzed after 5 hr of fasting.
(M–P) (M) Liver TG, (N) C18:1 in total lipid, (O) C18:1 in CE, and (P) C18:1 in TG. Data are represented as mean ± SEM. *p < 0.05.HFD-Fed and Calorie-Restricted T5KO Mice Display
Elevated MUFA-Enriched Hepatic Neutral Lipids
Diets rich in saturated fat are a risk factor for insulin resistance,
obesity, and hepatic steatosis. Accordingly, we demonstrated
exacerbated metabolic syndrome and hepatic steatosis in
T5KO mice fed HFD (Vijay-Kumar et al., 2010). Because of the
substantial reduction in plant-derived fiber in HFD, we envi-
sioned that such diets might influence hepatic lipids. After
8 weeks on a HFD, T5KO mice displayed hyperglycemia and in-
sulin resistance (Figures 3A–3C) with concomitant increases inCell Mserum TC and TG (Figures 3D and 3E). Moreover, elevated liver
TG, total C18:1, and C18:1 in the TG fraction (Figures 3F–3H)
were observed in comparison to HFD-fedWTmice. Interestingly,
the HFD did not increase C18:1 in the CE fraction of liver lipids
in HFD-fed T5KO mice (Figure 3I), as was observed in T5KO
mice fed lab chow. Another major difference observed with
the HFD was a reduction in total lipid C18:2 in T5KO mice
(Figure 3J). A decreasing trend in C20:4 in the liver total lipid
fraction of T5KO mice was observed in comparison to WT
littermates (Figure 3K), suggesting altered delta-6 desaturaseetabolism 22, 983–996, December 1, 2015 ª2015 Elsevier Inc. 987
Figure 4. Hepatic Neutral Lipid Enrichment of C18:1 in T5KO Mice Is Microbiota Dependent
Age matched male T5KO mice and their WT littermates (4 week old, n = 5) were treated with broad-spectrum antibiotics (ampicillin and neomycin) in drinking
water for 8 weeks and analyzed for liver lipids.
(A–D) (A) Liver TG, (B) C18:1 in total lipid, (C) C18:1 in TG, and (D) C18:1 in CE. Hepatic lipids were analyzed in 12-week-old males (age- and sex-matched) GF-
T5KO mice and their WT littermates (n = 7).
(E–I) (E) Liver TG, (F) C18:1 in total lipid, (G) C18:1 in TG, (H) C18:1 in CE, and (I) Immunoblot for hepatic SCD1 in conventional (conv), antibiotics-treated, and GF-
T5KOmice and their WT littermates. Four-week-old male GF (Swiss Webster) WT mice (n = 5) were orally administered cecal microbiota from either WT or T5KO
mice and housed in specific pathogen-free conditions. Hepatic C18:1 in lipid fractions was analyzed 6 weeks after transplantation.
(J–L) (J) C18:1 in total lipid, (K) C18:1 in TG, and (L) C18:1 in CE. Data are represented as mean ± SEM. *p < 0.05.activity. Additionally, mRNA transcripts of hepatic Fas, Scd1,
Hmgcr, Foxo1, and Lcn2 were elevated in HFD-fed T5KO mice
(Figure 3L). There were no significant differences in the transcript
levels of lipogenic genes in adipose and skeletal muscles of
HFD-fed T5KO mice (Figures S3A and S3B). Colonic expression
of SCFA receptors and pro-inflammatory genes except iNos
were also comparable to WT mice (Figure S3C). Similar results
were obtained with HFD-fed male T5KO mice (data not shown).
Metabolic syndrome in T5KO mice is largely driven by hyper-
phagia; calorie restriction for 12 weeks normalized most of the
indices of metabolic syndrome in T5KO mice except insulin
resistance (Vijay-Kumar et al., 2010). Analysis of liver lipids and
fatty acid profiles of calorie-restricted WT and T5KO mice ex-
hibited an increase in liver TG and liver total C18:1 mainly in
TG and CE fractions (Figures 3M–3P) of T5KO mice in compari-
son to WT, suggesting that an increase in hepatic lipids might be
contributing to insulin resistance. Further, the PUFA C18:2 and988 Cell Metabolism 22, 983–996, December 1, 2015 ª2015 ElsevierC20:4 levels showed a decreasing trend in the liver total lipids
and TG and CE fractions as observed in ad libitum fed mice
(data not shown).
Oleate Enrichment in Hepatic Lipids of T5KO Mice Is
Microbiota Dependent
TLR5 is predominantly expressed on gut epithelial cells and
plays a key role in microbiota homeostasis (Vijay-Kumar et al.,
2007). Accordingly, T5KO mice exhibit 3-fold higher fecal
bacterial load (data not shown). To demonstrate the role of the
microbiota in liver lipogenesis, we eliminated 90% of bacteria
via antibiotics. Microbiota ablation ameliorated the majority of
symptoms of metabolic syndrome in T5KO mice and, moreover,
normalized hepatic TG and C18:1 in total lipid and TG and CE
fractions (Figures 4A–4D).
These observations were further confirmed in GF-T5KO mice,
and their WT littermates as GF-T5KO mice did not exhibit eitherInc.
symptoms of colitis or indices of metabolic syndrome (Figures
S4A–S4E). Notably, hepatic TG, total C18:1 and C18:1 in TG
and CE fractions in GF-T5KO mice were comparable to WT
littermates (Figures 4E–4H). Interestingly, the levels of C18:1 (in
both strains) was substantially reduced (50%) with concomi-
tant reduction of hepatic SCD1 expression inmicrobiota-ablated
and GF mice when compared to conventional mice (Figure 4I).
These results suggest that themicrobiota or its metabolites likely
play a key role in de novo synthesis of hepatic MUFA.
In a similar line, we asked whether the cecal microbiota of
T5KO mice is sufficient to modulate hepatic lipogenesis upon
transplant to GF-WT recipients. Cecal microbiota transplanta-
tion influenced hepatic lipid MUFA levels in GF-WT mice that
received either WT or T5KO cecal microbiota. As shown in Fig-
ures 4J–4L, total lipid, TG, and CE C18:1 levels in GF-WT mice
that received T5KO cecal microbiota were significantly higher
than theWT cecal microbiota recipients. As observed in conven-
tional mice, transplantation of cecal microbiota resulted in a
greater than 50% increase in C18:1 level in GF-WT recipients.
However, this effect was more profound in T5KO mice cecal re-
cipients, suggesting that the T5KO microbiota is sufficient to
induce hepatic neutral lipid C18:1enrichment (Figures 4J–4L).
The Increased Hepatic MUFA in T5KO Mice Is
Associated with Elevated Cecal SCFA
Gut microbiota plays a key role in host energy homeostasis
by generating SCFA via fermentation of dietary fiber, which
serves as substrate for lipid biosynthesis (den Besten et al.,
2013a). The SCFAs are utilized by colonocytes or absorbed effi-
ciently in the colon (den Besten et al., 2013b). Therefore, we per-
formed metabolic profiling of intestinal contents by 1H NMR. As
shown in Figures 5A–5E, cecal contents of T5KOmice displayed
increased SCFA, specifically butyrate and propionate. Similar
results were observed in calorie restricted T5KO mice (data
not shown). Surprisingly, there was no significant difference
observed in themajor luminal SCFA acetate in the cecal contents
of both strains. As expected, fecal metabolites by 1H NMR and
fatty acid analysis by GC did not reveal any significant differ-
ences in WT and T5KO mice (Figure S5A; Table S2), indicating
SCFA produced in ceca were absorbed in the colon. In support
of this notion, we observed elevated colonic mRNA transcripts of
SCFA receptors (G protein-coupled receptor (Gpr)41 and 43;
Figure 5F) and increased SCFA (propionate and butyrate) in
the hepatic portal vein serum of T5KO mice (Figure 5G). How-
ever, no change in Gpr109A and Na+-coupled transporter of
SCFA Slc5a8 was observed between WT and T5KO mice (Fig-
ures S5B and S5C). These results suggest that T5KO mice,
which have an increasedmicrobial burden, utilizemore oligosac-
charides and generate higher levels of SCFA. To extend our
demonstration how increased availability of SCFA to liver affects
de novo lipogenesis (DNL), we fed 13C-acetate to WT and T5KO
mice to measure label incorporation into liver and plasma lipids.
The feeding achieved an overall enrichment of the C16:0-
McLafferty ion+1 (m/Z = 75) of 1.17% ± 0.07% above back-
ground. Under these conditions, the proportion of label appear-
ing in C16:0 was increased in T5KO mice (Figures 5H and 5I),
indicating SCFA contributes a greater fraction of TG in both the
liver and plasma pools. This is apparent in serum TG of T5KO
mice (Figure 5I), where increased serum TG-C16:0 results fromCell Man increased utilization of SCFA above that observed in WT.
This indicates that the increased delivery of SCFA to hepato-
cytes combines with the observed increase in synthetic capacity
(Figure 2) to result in increased DNL in T5KO mice.
Dietary SCFA Upregulate Hepatic SCD1 and Aggravate
Metabolic Syndrome in T5KO Mice
Dietary SCFA can regulate gut inflammation (Maslowski et al.,
2009; Smith et al., 2013). SCFA produced in the cecum partake
in hepatic lipogenesis in bothmice and human (den Besten et al.,
2013a; Wolever et al., 1989). Therefore, we next asked whether
dietary SCFAwould protect from low-grade inflammation or pro-
mote metabolic syndrome in T5KO mice. We administered a
combination of acetate, butyrate, and propionate in drinking wa-
ter for 21 days, as previously described (Smith et al., 2013), and
observed that T5KO mice on SCFA treatment exhibited further
increase in body weight, fat pad, blood glucose, and insulin
resistance (Figures 6A–6D) compared to vehicle-treated T5KO
mice. In agreement with a recent report (Frost et al., 2014), we
observed a significant reduction in food intake in both WT and
T5KO mice receiving dietary SCFAs (Figure 6F). Dietary SCFAs
further elevated serum TC and TG in T5KO mice (Figures 6G
and 6H). Interestingly, no significant differences were observed
in the above parameters in WT mice with or without dietary
SCFA (Figures 6A–6H) except reduced food intake. Taken
together, these results suggest that SCFA participate in hepatic
lipogenesis and contributing to insulin resistance in T5KO mice.
We next analyzed how SCFA supplementation impacted the
liver lipids. Similar to data from the serum, T5KO mice fed
SCFA showed an increase in liver TG and CE except liver FC
(Figures 6I–6K) compared to vehicle-treated T5KO mice. Inter-
estingly, dietary SCFA further increased liver SCD1 in T5KO
mice (Figure 6L). Serum insulin remains unaltered in SCFA-fed
T5KO mice (Figure 6E), suggesting that the increased hepatic
SCD1 in these mice could be due to more SCFA availability as
substrate. Further, dietary SCFA increased hepatic total C18:1,
TG C18:1 and CE C18:1 in T5KO mice when compared vehicle
given mice (Figures 6M–6O). Hepatic palmitoleate (C16:1) was
also elevated in T5KO mice that received SCFA (2.36 ± 0.19,
T5KO versus 2.91 ± 0.1, T5KO+SCFA). However, no change in
adipose tissue fatty acid composition was observed in T5KO
mice given SCFA (data not shown). Expression of hepatic inflam-
matory genes and lipogenic genes in liver (Figure 6P), adipose,
and skeletal muscles (Figures S6A and S6B) were unaltered in
SCFA-fed T5KOmice.Moreover, colonic expression of SCFA re-
ceptors/transporters and pro-inflammatory genes also remained
unaltered, with the exception of Lcn2, which is reduced, in T5KO
mice fed SCFAs (Figure S6C). Additionally, colonic MPO activity
(Figure S6D) and gut bacterial load (Figure S6E) remained un-
changed in T5KO mice fed with SCFAs.
Hepatic Stearoyl-CoA Desaturase 1 Deficiency
Improves Metabolic Syndrome in T5KO Mice
T5KO mice displayed substantial upregulation of hepatic SCD1
as well as increased presence of its product C18:1 in the hepatic
lipid, suggesting its potential involvement in metabolic syn-
drome. Therefore, to investigate the role of hepatic SCD1,
we generated liver-specific Scd1-deficient T5KO mice (T5KO-
Scd1DHep) and monitored for indices of metabolic syndrome inetabolism 22, 983–996, December 1, 2015 ª2015 Elsevier Inc. 989
Figure 5. Metabolic Profiles of Cecal Contents Are Altered in T5KO Mice
(A and B) Typical 600 MHz 1H NMR spectra of cecal contents from male (A) T5KO and (B) WT mice (20 week old, n = 10 to 11).
(C–E) (C) OPLS-DA score plot (left) and correlation coefficient loading plot (right) showing the discrimination between 1H NMR spectra of cecal contents from
T5KO andWTmice, respectively (jrj cutoff value is 0.602, n = 10 forWT group and n = 11 T5KOmice group; C. R2X = 0.56, Q2 = 0.58; CV-ANOVA: p = 1.893 103).
Keys: 1, n-butyrate; 2, propionate; 3, isoleucine; 4, leucine; 5, valine; 6, ethanol; 7, lactate; 8, alanine; 9, lysine; 10, acetate; 11, proline; 12, bile acids; 13,
succinate; 14, pyruvate; 15, trimethylamine (TMA); 16, creatine; 17, a-ketoglutarate; 18, methanol; 19, oligosaccharides & amino acids; 20, a-glucose;
21,raffinose; 22, stachyose; 23, uracil; 24, taurine; 25, glycine; 26, uridine; 27, fumarate; 28, tyrosine; 29, choline; 30, methionine; 31, phenylalanine; 32, histidine;
33,urocanate; 34, adenine; 35,adenosine; 36, nicotinurate. Relative abundance of (D) SCFA (propionate and butyrate) and (E). oligosaccharides, glucose,
raffinose, and stachyose in cecal content extracts from WT and T5KO mice.
(legend continued on next page)
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Figure 6. Dietary SCFA Aggravates Metabolic Syndrome in T5KO Mice
Age-matched male T5KOmice and their WT littermates (16 week old, n = 6) received either amixture of SCFA (67.5 mM sodium acetate, 40 mM sodium butyrate,
and 25.9 mM sodium propionate) or equimolar sodium chloride in drinking water for 21 days.
(A–H) (A) Percent increase in body weight, (B) fat pad, (C) 15 hr fasting blood glucose, (D) insulin sensitivity test, (E) 5 hr fasting serum insulin, (F) food intake, (G)
serum TC, and (H) serum TG. Hepatic lipids were analyzed in 5 hr fasted mice.
(I–P) (I) TG, (J) CE, (K) FC, (L) immunoblot represents hepatic SCD1, (M) C18:1 in total lipid, (N) C18:1 in CE, (O) C18:1 in TG, and (P) mRNA expression of hepatic
lipogenic, inflammatory, and insulin resistance genes. Data are represented as mean ± SEM. *p < 0.05.comparison to Scd1 floxed T5KO mice (T5KO-Scd1fl/fl). Most
notably, T5KO-Scd1DHep mice exhibited reduced body weight
and abdominal adiposity coupled with improved insulin resis-
tance when compared to T5KO-Scd1fl/fl mice (Figures 7A–7D).
Even though serum insulin, TC, and TG levels were unaltered,
hepatic TGs and CEs were reduced in T5KO-Scd1DHep (Figures(F) Colonic expression of SCFA receptor in T5KO and their WT littermates (n = 1
(G) SCFA concentration in hepatic portal vein serum (n = 6–8).
(H and I) 13C-acetate label in animals fed 13C-sodium acetate (0.3 M) in drinking
(H) Fractional enrichment of C16:0 using C16:0 as the primary end product of DN
(I) Absolute concentration of C16:0 in liver and plasma TG. Data are represented
Cell M7E–7I). However, there was no change in hepatic FC (Figure 7J),
indicating that non-hepatic SCD1 activity might be able to main-
tain serum lipids. As expected, liver total, TGs, and CE C18:1
level was substantially reduced (Figures 7K–7M) with a concom-
itant increase in total hepatic C18:0 and total C18:2 in T5KO-
Scd1DHep (Figures 7N and 7O). Moreover hepatic palmitoleate0).
water for 4 days (n = 5).
L and the fractional enrichment as an estimate of fractional synthesis.
as mean ± SEM. *p < 0.05.
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Figure 7. Deletion of Hepatic Scd1 in T5KO Mice Protects against Metabolic Syndrome
LiverScd1-deficientWT (WT-Scd1DHep), T5KO (T5KO-Scd1DHep), and control (WT-Scd1fl/fl & T5KO-Scd1fl/fl) mice (male, n = 4–6) weremaintained on lab chow for
20 weeks.
(A–G) (A) Immunoblot (upper panel) and bar graph representing the hepatic expression of SCD1 at protein and mRNA level, respectively. (B) Body weight, (C)
percent fat pad, (D) insulin sensitivity test, (E) fasting serum insulin, (F) serum TC, and (G) serum TG. Hepatic lipids were analyzed in 5 hr fasted mice.
(H–P) (H) Liver TG, (I) CE, (J) FC, (K) total C18:1, (L) TG C18:1, (M) CE C18:1, (N) total C18:0, (O) total C18:2, and (P) mRNA expression of hepatic lipogenic,
inflammatory, and insulin resistance genes. Data are represented as mean ± SEM. *p < 0.05.(C16:1), was reduced in T5KO-Scd1DHep mice (2.27 ± 0.07,
T5KO-Scd1fl/fl versus 1.96 ± 0.09, T5KO-Scd1DHep). The hepatic
transcripts of pro-inflammatory genes and the marker of in-
sulin resistance Foxo1 were reduced in T5KO-Scd1DHep mice
(Figure 7P). Additionally, protein level of GLUT4, an insulin-
responsive gene, was augmented in skeletal muscle of T5KO-
Scd1DHep mice (Figure S7A), suggesting that liver Scd1 deletion
in T5KO mice is able to rescue the skeletal muscle insulin re-
sistance. However, GLUT4 expression was unaltered in adi-
pose tissue of T5KO-Scd1DHep in comparison to T5KO-Scd1fl/fl
mice (data not shown). Moreover, expression of lipogenic genes
remained unaltered in liver, adipose, and skeletal muscle of992 Cell Metabolism 22, 983–996, December 1, 2015 ª2015 ElsevierT5KO-Scd1DHep mice (Figures 7P, S7B, and S7C, respectively).
Similarly, the expression of colonic SCFA transporters and pro-
inflammatory genes alongwith colonicMPO activity, food intake,
and gut bacterial load remained unaltered in T5KO-Scd1DHep
mice when compared to T5KO-Scd1fl/fl mice (Figures S7D–
S7G). As expected, C18:1 level was reduced in hepatic total
and lipid fractions in WT-Scd1DHep mice when compared to
WT-Scd1fl/fl. However, we did not observe any significant
change in the metabolic-syndrome-related parameters between
these groups (Figures 7A–7P). Altogether, our results suggest
that loss of TLR5 results in a microbiota-generated increase
in SCFAs. In turn, the increase in SCFA may drive hepaticInc.
SCD1-mediated lipogenesis, consequently promoting insulin
resistance and inflammation in T5KO mice.
DISCUSSION
Gut microbiota is known to play a key role in the host energy
homeostasis and is thus considered an environmental risk factor
for metabolic diseases. Accordingly, mice deficient in TLR5
develop an altered microbiota that promotes metabolic syn-
drome. Herein, we report a potential molecular mechanism
involving elevated C18:1 hepatic neutral lipids underlying the
development of metabolic syndrome in T5KO mice. Such
elevated hepatic C18:1 levels likely result, at least in part, from
augmented SCD1 expression. We further observed that hepatic
enrichment of oleate is microbiota dependent.
The cecum is a transient reservoir for digested food and
therefore contains the majority of complex dietary fiber that
undergoes anaerobic bacterial fermentation that generates ace-
tate, propionate, and butyrate in molar ratio of 60:20:20 (Cum-
mings et al., 1979). Recent studies demonstrate a direct link of
obesogenic dysbiosis (i.e., altered Firmicutes/Bacteroidetes ra-
tio with metabolic syndrome in both mice and humans) (Ley
et al., 2006; Turnbaugh et al., 2006). We observed altered spe-
cies primarily in Firmicutes and Bacteroidetes phyla in T5KO
mice when compared to their WT littermates, but relative abun-
dance of these phyla was unaltered (Vijay-Kumar et al., 2010),
suggesting that elevated gut microbiota along with altered
bacterial species might contribute to increased cecal SCFA
generation in T5KO mice. These SCFA not only serve as a fuel
for intestinal epithelia (specifically butyrate) (Blottie`re et al.,
2003), but also contribute additional sources of energy to the
host (den Besten et al., 2013b). A recent study using stable iso-
topes of SCFA demonstrated that acetate and butyrate are
lipogenic whereas propionate is gluconeogenic (den Besten
et al., 2013a) in mice. Specifically, this study showed that cecal
acetate and butyrate contribute to synthesis of hepatic palmitate
and cholesterol. In a similar vein, 1H NMR-based metabolic
profiling of cecal content showed considerably elevated levels
of butyrate and propionate accompanied with a decreasing
trend of oligosaccharides in T5KO mice. Increased expression
of colonic SCFA receptors, particularly Gpr41 and Gpr43, af-
fords efficient absorption of these SCFAs and promoting the
inflammatory response via MAP kinase signaling in T5KO mice
(Kim et al., 2013). Acetate levels in cecal contents of T5KO
mice did not differ significantly in comparison to WT, suggesting
its rapid conversion into butyrate by the gut bacteria (den Besten
et al., 2013a). Previously, we showed no difference in either en-
ergy content in feces (bomb calorimetry) or SCFA levels in the
cecal contents of T5KO mice and their WT littermates via GC-
MS (Vijay-Kumar et al., 2010). The discrepancy could be due
to differences in collection of samples from previous studies,
including (i) age of the mice, (ii) ad libitum fed mice, (iii) use of
wet rather than dry stools, or (iv) differences in processing of
samples for analysis with 1H NMR. In this study, using a metab-
olomic approach, we found that T5KO mice with increased
microbiotal load generated substantial levels of SCFA in the
cecum. This is transferred to the liver and contributes to
increased hepatic DNL. Notably, the relative contribution of ac-
etate to lipogenesis was more in T5KO mice. It is likely that theCell Mgut-derived SCFA drive increased lipogenesis by provision of
greater amounts of substrate for the elevated lipid synthetic ma-
chinery in T5KO mice.
Several studies have demonstrated that SFA C16:0 and
C18:0, dietary or end products of DNL, are lipotoxic (Nolan
and Larter, 2009; Shi et al., 2006). Increased SCFAs serve as
substrates for SFA synthesis, which are converted into less lipo-
toxic MUFA via SCD1 (Miller et al., 2005) and play a role in the
development of obesity (Poudyal and Brown, 2011). Notably, he-
patic SCD1 level is substantially reduced in GF and microbiota-
ablated WT and T5KO mice, indicating that liver SCD1 is partly
regulated via gut microbial metabolites. Accordingly, our results
indicate that dietary SCFA aggravates the metabolic syndrome
phenotype in T5KO mice probably via overproduction of SFA
from SCFA.
The conversion of SFA into MUFA is known to prevent nega-
tive feedback inhibition of fatty acids (palmitate) on ACC (Ogi-
wara et al., 1978). The blockade of SFA removal as MUFA in
Scd1KO mice underlies its lean phenotype. Although T5KO
mice exhibited elevated C18:1-enriched hepatic neutral lipids,
those lipid species were not enriched with palmitoleate (C16:1
n7), a minor product of SCD1. It is interesting to note that
C16:1 has been shown to act as a lipokine, strongly induces
muscle insulin action, and suppresses hepatic lipogenesis in
mice (Cao et al., 2008). In addition, adipocyte-derived oleate
(18:1 n9), but not palmitoleate (16:1 n7), mediates inflammation
in macrophages and adhesion responses in endothelial cells
(Liu et al., 2010).
Deletion of SCD1 or supplementing leptin toOb/Obmice ame-
liorates obesity (Cohen et al., 2002). Interestingly, T5KOmice ex-
hibited upregulation of a spectrum of hepatic lipogenic enzymes,
including SCD1, even though they are hyperleptinemic (Vijay-Ku-
mar et al., 2010), suggesting they may be in a state of leptin
resistance. Elevated hepatic SCD1 in T5KO mice may be driven
by increase in (i) stability of this protein, (ii) insulin level, (iii) pre-
cursor (e.g., SCFA) availability (Alberts et al., 1974; Jeffcoat
et al., 1979; Mziaut et al., 2000), (iv) low-grade hepatic inflamma-
tion, and (v) Srebp1c, a transcription factor known to stimulate
lipogenic genes including Scd1 in hepatocytes. Accordingly,
we demonstrated that deletion of hepatic Scd1 prevented accu-
mulation of C18:1 and improved metabolic syndrome in T5KO
mice. Taken together these results reinforce the concept that
the microbiota-generated SCFA contribute, at least in part, to
hepatic lipogenesis in T5KO mice. MUFA generated via SCD1
activity, but not dietary MUFA, function as endogenous fatty
acid amide hydrolase (FAAH) inhibitor and thereby increases
hepatic arachidonoylethanolamide (AEA), which induces insulin
resistance by activating liver endocannabinoid/CB1 receptor
(Liu et al., 2013). Endogenous MUFA, synthesized by SCD1,
but not dietary MUFA is required for hepatic TG synthesis, as
oleate-enriched diet failed to restore hepatic TG level in global
Scd1-deficient mice (Miyazaki et al., 2001). These observations
support the notion that there is a difference in the metabolic
fate of endogenously produced versus ingested metabolites.
HFD aggravated metabolic syndrome and caused insulitis and
hepatic steatosis in T5KO mice. Surprisingly, HFD-fed T5KO
mice displayed modest increase in C18:1; this could reflect a
reduced supply of SCFA as the HFD lacks plant-derived com-
plex carbohydrates. However, the HFD used in this study isetabolism 22, 983–996, December 1, 2015 ª2015 Elsevier Inc. 993
rich in palmitate (26%) and oleate (44%), which together may be
enough to maintain C18:1 level on a higher side in T5KO mice. A
recent study by Wichmann et al. (2013) demonstrated that total
SCFA in cecal contents is greatly reduced (>50%) in HFD-fed
mice compared to chow-fed mice. Although there was a sub-
stantial reduction in EFA C18:2 and C20:4 in PL fractions of
HFD-fed T5KO mice, they were far from EFA deficiency, as indi-
cated by no detectable levels of eicosatrienoic acid (C20:3 n9), a
surrogate marker of EFA deficiency.
Altogether, metabolic syndrome in T5KO mice seems to be
orchestrated by increased fermentation and low-grade chronic
inflammation with elevated MUFA in hepatic neutral lipids. Abro-
gation of spontaneous inflammation and metabolic syndrome in
GF T5KOmice indicates that themicrobiota is involved in both of
these processes. Previous studies elegantly demonstrate that
dietary SCFA prevent obesity and associated metabolic abnor-
malities by suppressing hepatic lipogenesis, fat accumulation,
and reducing appetite in mice (den Besten et al., 2015; Frost
et al., 2014; Kimura et al., 2013) and improve colonic inflamma-
tion (Arpaia et al., 2013; Furusawa et al., 2013; Singh et al., 2014;
Smith et al., 2013). Conversely, elevated fecal SCFA correlate
with obesity metabolic syndrome factors in humans (Fernandes
et al., 2014; Teixeira et al., 2013). Similar to our finding that
SCFA aggravate metabolic syndrome in T5KO mice, long-term
adaptation of serum lipid responses occur in type 2 diabetic sub-
jects receiving fiber-rich diet; serum acetate correlates with
plasma TG and cholesterol in these subjects (Wolever et al.,
2002). In the present study, we observed that continuous over-
production of SCFA by gut bacterial fermentation contribute in
hepatic lipid accumulation and thus metabolic syndrome in
mice with elevated gut bacterial load, low-grade chronic inflam-
mation, and augmented expression of hepatic lipogenic genes.
According to the available literature, SCFAs are beneficial
in metabolic syndrome, but in certain contexts where uncon-
trolled, prolonged generation of SCFAs due to increased
microbiotal load as in T5KO mice may have detrimental effects.
Herein, we envisage that this prolonged over-production of
SCFA in T5KO mice may lead to ‘‘metabolic adaptation,’’ as
observed with elevated hepatic SCD1, to convert them into lipid
species.
Although our favored interpretation of our data are that
elevated gut microbial metabolites (i.e., SCFA) and low-grade
chronic inflammation promote augmented hepatic lipogenesis
and thus metabolic syndrome of T5KO mice, alternative mecha-
nisms are possible. Notably, we cannot exclude the important
role of selective hepatic insulin resistance and elevated serum in-
sulin, which are shown to promote lipogenesis in liver (Biddinger
et al., 2008) in driving the metabolic syndrome in T5KO mice. In
any case, themicrobiotal-hepatic axismay not account for all the
reasons for which T5KOmice develop metabolic syndrome, and
there is a possibility that other yet unknown processes/pathways
(e.g., leptin resistance), which are not examined by our study
design, may also contribute to the observed metabolic syn-
drome in T5KOmice; the relative extent of contribution by themi-
crobiotal-hepatic axis to the observed metabolic syndrome will
remain unknown unless and until these other processes/path-
ways either within the liver or elsewhere are deciphered. Present
study highlights the role of the gut microbiota-liver axis in driving
metabolic diseases, specifically in conditions with innate im-994 Cell Metabolism 22, 983–996, December 1, 2015 ª2015 Elseviermune deficiency coupled with microbiotal overload and suscep-
tibility to spontaneous inflammation. Collectively, our results
suggest that balanced pharmacologic manipulation of hepatic
SCD1 (Brown and Rudel, 2010) may be useful in the treatment
of metabolic diseases with a caution to avoid secondary accu-
mulation of lipotoxic SFAs.
EXPERIMENTAL PROCEDURES
All reagents and detailed methods are described in the Supplemental
Information.
Mice, Diet, Treatments, and Metabolic Parameter Analysis
The institutional animal ethical committees at Emory University, Georgia State
University and The Pennsylvania State Universities approved the animal ex-
periments. T5KOmice and their WT littermates were maintained in the specific
pathogen-free condition in Emory, Georgia State, and Pennsylvania State Uni-
versities. Mice were maintained on lab chow (Lab Diets 5001), HFD (D12492,
Research Diets Inc.), or calorie restriction.
Serum lipids were monitored in 5 hr fasted serum using commercial kits
(Randox Laboratories). All lipid and fatty acid quantification were performed
at mouse metabolic phenotyping centers (MMPC) lipid laboratory, Vanderbilt
University. Serum insulin was quantified by an ELISA kit from EMD Millipore.
To measure insulin sensitivity, insulin was injected (0.25 units/kg body
weight, intraperitoneally) in 5-hr-fasted mice, and then blood glucose was
monitored at 0, 30, 60, 90, and 120 min after the insulin injection (Vijay-Kumar
et al., 2010).
Quantitative RT-PCR
Total RNA was isolated from tissues using Tri-reagent (Invitrogen). cDNA was
synthesized by cDNA synthesis kit (Superscript VILO, Invitrogen). Real time
PCR was performed using Step One Plus Real-Time PCR System (Applied
Biosystems) in a reaction mixture of cDNA, SYBR green master mix, and
mouse-specific oligonucleotides (Table S1).
Immunoblotting
Tissues (50 mg) were homogenized in 0.5 ml RIPA buffer (Cell Signaling) with
protease inhibitors (Roche) and fractionated on SDS-PAGE and then trans-
ferred to PVDF membrane. After blocking with non-fat milk (5%) blots were
incubated overnight at 4C with anti-mouse SCD-1, AKT, pAKTThr308, or
GLUT4. The blots were developed by chemiluminiscent reagent. b-actin and
GAPDH was used as a loading control.
Transplantation of Cecal Microbiota into GF WT Mice
Microbiota transfer was performed as described previously (Vijay-Kumar et al.,
2010). Briefly, cecal contents from age- and sex-matched T5KOmice and their
WT littermates were suspended in 2.5 ml PBS (at 37C) and administered
(0.1 ml/mouse) to male GF-WT mice.
SCFA Estimation
Hepatic portal serum was collected from age- and sex-matched T5KO mice
and their WT littermates and its SCFA content was quantified as in Zheng
et al. (2013). In brief, serumwasmixed with NaOH (0.005M) containing internal
standard (caproic acid-d3, 5 mg/ml). A mixture of 1-propanol: pyridine (3:2, v/v)
and propyl chlorformate were subsequently added to the glass tube.
After derivatization, at 60C for 75 min, the derivatives were extracted with
hexane. The upper hexane layer was transferred to a autosampler vial and
SCFA was measured using an Agilent 7890A GC-MS spectrometer (Agilent
Instruments).
NMR Spectroscopy
Mice cecal and fecal contents were homogenized and extracted in PBS
containing 50% D2O, 0.002% (w/v) of sodium 3-(trimethylsilyl) propionate-
2,2,3,3-d4 (TSP) as described previously (Wu et al., 2010). All 1H NMR spectra
of sample extracts were recorded at 298 K using a Bruker Avance III 600 MHz
NMR spectrometer. Multivariate data analysis was carried out with the
SIMCAP+ software (version 13.0, Umetrics, Sweden).Inc.
Analysis of 13C Label Acetate in Fatty Acids
Male T5KO and their WT littermates were fed with 13C sodium acetate (0.3 M,
in drinking water) up to 4 days. Plasma and liver fatty acids were extracted and
methylated using a modification of Morrison and Smith (1964) and quantified
by through GC-MS (Shimadzu Corporation). Tri-heneicosanoin was used as
a surrogate in plasma samples to adjust for extraction efficiency. To detect
13C enrichment in palmitic acid (C16:0) area counts were obtained for the
McLafferty ion (MCI) and the MCI+1 (m/z = 74 and 75, respectively) (Sharkey
et al., 1959) using GC MS solution software (Shimadzu Corporation).
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2015.09.028.
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